Increased glycoprotein acetylation is associated with high cardiac event rates: analysis with coronary computed tomography angiography

Abstract

Objective:Glycoprotein acetylation (GlycA), an emerging inflammatory biomarker, has been used as an indicator of cardiovascular disease. Our research aimed to evaluate the correlation between GlycA and coronary artery disease (CAD) using coronary computed tomography angiography (CCTA).Methods:In the present study, a total of 342 patients were enrolled, and each of them underwent CCTA. The correlation between GlycA and major adverse cardiac events (MACE) was detected via Cox’s proportional hazards models. Based on differences in the GlycA level, patients were categorized into three groups (T1, T2, and T3).Results:Compared with the group with the lowest GlycA level (T1), the group with the highest GlycA level (T3) exhibited stronger atherosclerotic pressure involving the extent of atherosclerotic plaque and risk of obstructive CAD. In addition, the patients in the T3 group had a greater chance of experiencing MACE and higher all-cause mortality than those in the T1 group. Among patients without CAD who underwent CCTA, those with high GlycA levels experienced elevated atherosclerotic stress and heightened risk of MACE compared with those with low GlycA levels.Conclusion:These results suggest that serum GlycA is significantly associated with the long-term clinical results of patients with no known CAD undergoing CCTA. The risks of death and experiencing MACE increase among patients with high GlycA levels.

Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials

“…Following this, placebo patients were switched to secukinumab for the remainder of the 52-week study. Evaluation with 18 F-FDG PET/CT scans revealed no significant changes in TBR of the aorta following secukinumab treatment. Furthermore, no significant differences at week 12 in any markers of inflammation, insulin resistance, diabetic predictors, or adiposity were noted.…”

“…Following 12 weeks of treatment, both adalimumab and phototherapy resulted in significant decreases in serum CRP and IL-6 when compared to placebo (p \ 0.05). Furthermore, treatment with adalimumab for 12 weeks also resulted in significant reductions in TNF-a, a key proinflammatory cytokine, and glycoprotein acetylation (GlycA), which is positively associated with risk of death and major cardiovascular events [vs. placebo (p \ 0.01)] [18]. Following 52 weeks of treatment with adalimumab, significant improvements were noted in the biomarker levels of TNF-a, GlycA, and CRP, but significantly negative impacts were seen in both IL-6 and high-density lipoprotein particle (HDL-P) levels (p \ 0.05).…”

“…The impact of secukinumab on vascular inflammation via 18 F-FDG PET/CT scans and serum cardiometabolic biomarkers was evaluated in a randomized, double-blind, placebocontrolled study of psoriasis patients [22]. Patients were randomized to either secukinumab 300 mg or placebo for the first 12 weeks.…”

“…The effect of ustekinumab on aortic vascular inflammation was evaluated via TBR with 18 F-FDG PET/CT scans and biomarkers of systemic inflammation, lipids, and glucose metabolism in a phase IV, randomized, double-blind, placebo-controlled trial [25]. In total, 43 patients were randomized to either ustekinumab for ustekinumab for an additional 52 weeks.…”

Gamma-glutamyl transferase to albumin ratio can predict severity of coronary artery disease detected by coronary computed tomography angiography

“…GAR may be helpful to diagnose and determine the severity of the CAD. Coronary computed tomography angiography (CCTA) is a non-invasive test that offers substantially accurate results regarding the anatomy of coronary arteries and provides additional information about the presence, severity, and morphology of coronary plaques (10)(11)(12)(13)(14). Guidelines recommend CCTA as the first-line imaging tool to evaluate acute chest pain and stable angina pectoris in patients with mild to moderate risk (15).…”